Compound ID | 2871
Synonym(s): MET-102 | ASN-1733
Class: Membrane-active agent
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Membrane-active agent. Disrupts integrity of cell membrane and inhibits NDM |
| Target Pathogen: | Active against Staphylococcus aureus, Escherichia coli, and other NDM-producing strains |
| Description: | Synthetic compound derived from nitroxoline (5-nitro-8-hydroxyquinoline) scaffold; shows synergistic effect with meropenem against NDM-1 producing strains; cytotoxic (IC50) and haemolytic activity only at concentrations >12xMIC50 |
| Institute where first reported: | Asieris Pharmaceuticals |
| Year first mentioned: | 2024 |
| Highest development stage: | Phase 1 (to begin in Australia in 2024) |
| Development status: | Active |
| External links: | |
| Guide to Pharmacology: | APL-2301 |
| Citation: | https://www.tandfonline.com/doi/full/10.1080/22221751.2023.2294854 |